C9 and cancer: In addition, there was no difference in the killing ability of C9-CAR-NK92 cells and CDH17-CAR-NK92 cells against the CDH17 surface-negative cancer cell line PC3, suggesting that CDH17-CAR-NK92 kill tumor cells by specifically targeting CDH17 (Fig. 2G).